What are the side effects of Infliximab-ABDA?

Infliximab-ABDA, a biosimilar to infliximab, is used to treat a variety of inflammatory conditions such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. While it offers significant relief for many individuals suffering from these chronic conditions, it is essential to be aware of the potential side effects that may accompany its use. Understanding these side effects can help patients manage their treatment more effectively and make informed decisions alongside their healthcare providers.

Common Side Effects:
One of the most frequently reported side effects of Infliximab-ABDA is infusion-related reactions. These reactions can occur during or within a couple of hours post-infusion and include symptoms like fever, chills, itching, and rash. While these are generally mild and manageable, it is crucial to inform your healthcare provider if they occur.

Another common side effect is respiratory infections, including sinus infections and upper respiratory tract infections. Patients might experience symptoms such as a runny nose, sore throat, or cough. These infections are typically mild but can be more severe in some cases.

Gastrointestinal issues are also common side effects. Patients may experience abdominal pain, nausea, and diarrhea. While these symptoms can be uncomfortable, they are usually transient and subside with time.

Serious Side Effects:
Though less common, some side effects of Infliximab-ABDA can be serious and require immediate medical attention. One such side effect is an increased risk of serious infections. Infliximab-ABDA suppresses the immune system, which can make patients more susceptible to infections like tuberculosis (TB), bacterial sepsis, invasive fungal infections, and other opportunistic infections. It is crucial for healthcare providers to screen for TB and other infections before starting treatment with Infliximab-ABDA.

Another severe side effect is the potential for the development of malignancies. There have been reports of lymphoma and other cancers in patients receiving TNF blockers, including infliximab products. This risk is particularly noteworthy in patients with chronic obstructive pulmonary disease (COPD) and those with a history of heavy smoking.

Hepatotoxicity is another serious concern. Symptoms of liver problems include jaundice (yellowing of the skin or eyes), dark urine, severe fatigue, and upper abdominal pain. If any of these symptoms are observed, it is essential to contact a healthcare provider immediately.

Rare Side Effects:
Although rare, some patients may experience severe allergic reactions, including anaphylaxis. Symptoms of a severe allergic reaction include difficulty breathing, swelling of the face or throat, and hives. Immediate medical intervention is required in such cases.

There is also a rare but serious risk of developing demyelinating disorders, such as multiple sclerosis or Guillain-Barré syndrome. Symptoms of these conditions may include changes in vision, weakness in the legs, and numbness or tingling in the extremities.

Cardiovascular side effects, including heart failure, have been reported. Patients with pre-existing heart conditions should be closely monitored during treatment with Infliximab-ABDA. Signs of heart failure include shortness of breath, swelling of the ankles or feet, and sudden weight gain.

Monitoring and Management:
Due to the range of potential side effects, regular monitoring by healthcare providers is crucial for patients receiving Infliximab-ABDA. Blood tests may be conducted periodically to check for signs of infection, liver function, and other potential issues. Patients are also advised to communicate openly with their healthcare providers about any new or worsening symptoms.

In conclusion, while Infliximab-ABDA can significantly improve the quality of life for individuals with chronic inflammatory conditions, it is important to be aware of and manage its potential side effects. By staying informed and maintaining open communication with healthcare providers, patients can navigate their treatment with greater confidence and safety.